Clinically‐Relevant Static Magnetic Field Induces Release of Encapsulated Molecules from Magnetoliposomes
Source abstract
Abstract
ABSTRACT Magnetoliposomes (MLs) are known for their great potential in drug release under an alternating current (AC) magnetic field (MF). However, AC magnetic fields require specific setups that remain poorly implemented worldwide, contrary to direct currents (DC) that are present in widely used magnetic resonance imaging (MRI) devices. In this work, we evidence the feasibility of a drug release triggered by a 1.5 T constant MF, currently used in clinics. The structuration of magnetite nanoparticles (NPs) stabilized by surface adsorption of citric acid (Fe 3 O 4 :CA NPs), and an optional chitosan shell (Fe 3 O 4 :CA:CS NPs) to enhance cytocompatibility, was followed under a 1.5 T constant by small‐angle X‐ray scattering (SAXS), and dynamic light scattering (DLS). MLs encapsulating both Fe 3 O 4 :CA NPs and fluorescent carboxyfluorescein (CF), were also submitted to 1.5 T, and the CF fractional release was monitored. The effect of Fe 3 O 4 :CA:CS NPs addition externally to MLs in the suspension was investigated. Results evidenced that both Fe 3 O 4 :CA and Fe 3 O 4 :CA:CS NPs formed necklace‐like aggregates under DC MF. Fluorescence experiments demonstrated a significant CF release from MLs, which was enhanced by the addition of external NPs, while empty liposomes exhibited negligible releases. Finally, a biological evaluation of MLs and NPs revealed an excellent cytocompatibility.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Ginkgo biloba and Cashew Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
UMR 5223, Ingénierie des Matériaux Polymères (IMP) Université Claude Bernard Lyon 1, INSA Lyon Université Jean Monnet CNRS Villeurbanne France
Veterinary School of Lyon (VetAgro Sup) UPSP 2016.A104 Interactions Cellules Environnement Marcy l'Etoile France
Department of Radiation Oncology CH Lyon‐Sud Pierre‐Bénite France
Funding
Université Claude Bernard Lyon 1
References (60)
Show source-provided references
1. 10.1016/j.ijpharm.2021.12057110.1016/j.ijpharm.2021.120571 ↗
2. 10.1016/j.cis.2022.10275710.1016/j.cis.2022.102757 ↗
3. 10.1053/j.seminoncol.2004.08.00110.1053/j.seminoncol.2004.08.001 ↗
4. 10.1016/j.ajps.2014.09.00410.1016/j.ajps.2014.09.004 ↗
5. 10.1039/C9NR04669K10.1039/C9NR04669K ↗
6. 10.1016/j.ijpharm.2022.12221210.1016/j.ijpharm.2022.122212 ↗
7. 10.1016/j.tca.2019.17846210.1016/j.tca.2019.178462 ↗
8. 10.2147/IJN.S6886110.2147/IJN.S68861 ↗
9. Advanced Drug Delivery Reviews
10. 10.3390/molecules2704137210.3390/molecules27041372 ↗
11. 10.3390/pharmaceutics902001210.3390/pharmaceutics9020012 ↗
12. 10.1016/j.cis.2023.10293010.1016/j.cis.2023.102930 ↗
13. 10.1002/wnan.145010.1002/wnan.1450 ↗
14. 10.1016/j.jddst.2021.10291610.1016/j.jddst.2021.102916 ↗
15. 10.1080/17425247.2021.191598310.1080/17425247.2021.1915983 ↗
16. Recent Advances in Magnetoliposome for Heart Drug Delivery
17. 10.1016/j.bbagen.2017.02.02510.1016/j.bbagen.2017.02.025 ↗
18. 10.1515/ejnm-2014-004210.1515/ejnm-2014-0042 ↗
19. 10.1039/C5TB02191J10.1039/C5TB02191J ↗
20. 10.1039/B915651H10.1039/B915651H ↗
21. 10.1016/S1567-5394(01)00171-210.1016/S1567-5394(01)00171-2 ↗
22. 10.3389/fphar.2022.85443010.3389/fphar.2022.854430 ↗
23. 10.3109/02656736.2013.83675810.3109/02656736.2013.836758 ↗
24. 10.1080/02656736.2017.141250410.1080/02656736.2017.1412504 ↗
25. 10.3390/ma307405110.3390/ma3074051 ↗
26. 10.1007/s11051-012-0964-810.1007/s11051-012-0964-8 ↗
27. 10.1186/s12645-021-00086-810.1186/s12645-021-00086-8 ↗
28. 10.1039/D4MA00010B10.1039/D4MA00010B ↗
29. 10.1002/jbm.a.3177510.1002/jbm.a.31775 ↗
30. 10.1016/j.mtcomm.2025.11285210.1016/j.mtcomm.2025.112852 ↗
31. 10.3390/cancers1502034610.3390/cancers15020346 ↗
32. 10.3390/onco502002610.3390/onco5020026 ↗
33. 10.1016/j.critrevonc.2015.08.00310.1016/j.critrevonc.2015.08.003 ↗
34. 10.1016/j.ctrv.2015.05.00910.1016/j.ctrv.2015.05.009 ↗
35. 10.1039/C8NR09583C10.1039/C8NR09583C ↗
36. 10.1107/S160057751900490910.1107/S1600577519004909 ↗
37. 10.1039/C4FD00242C10.1039/C4FD00242C ↗
38. 10.1073/pnas.151144311210.1073/pnas.1511443112 ↗
39. 10.1063/1.491448410.1063/1.4914484 ↗
40. 10.3389/fmolb.2021.70341710.3389/fmolb.2021.703417 ↗
41. 10.1016/S0169-409X(99)00041-110.1016/S0169-409X(99)00041-1 ↗
42. 10.1016/0005-2736(94)90038-810.1016/0005-2736(94)90038-8 ↗
43. 10.1016/0005-2736(89)90078-310.1016/0005-2736(89)90078-3 ↗
44. 10.1109/TMAG.1981.106118810.1109/TMAG.1981.1061188 ↗
45. 10.1088/1742-6596/1389/1/01207010.1088/1742-6596/1389/1/012070 ↗
46. 10.1021/jp502227810.1021/jp5022278 ↗
47. 10.1371/journal.pone.008764910.1371/journal.pone.0087649 ↗
48. 10.1016/j.carbpol.2014.11.04210.1016/j.carbpol.2014.11.042 ↗
49. 10.1016/S0008-6215(00)00038-010.1016/S0008-6215(00)00038-0 ↗
50. 10.1021/bm025724c10.1021/bm025724c ↗
51. 10.1007/BF0029935210.1007/BF00299352 ↗
52. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
53. 10.1016/j.colsurfa.2025.13891910.1016/j.colsurfa.2025.138919 ↗
54. 10.1021/acsanm.3c0611810.1021/acsanm.3c06118 ↗
55. 10.1016/j.addr.2010.05.00610.1016/j.addr.2010.05.006 ↗
56. 10.1016/j.carbpol.2015.06.09610.1016/j.carbpol.2015.06.096 ↗
57. 10.1016/j.colsurfa.2017.12.04810.1016/j.colsurfa.2017.12.048 ↗
58. 10.1016/j.ijbiomac.2018.12.19510.1016/j.ijbiomac.2018.12.195 ↗
59. 10.1038/s41598-018-30264-510.1038/s41598-018-30264-5 ↗
60. 10.1016/j.rinp.2019.10265110.1016/j.rinp.2019.102651 ↗